Karen L.

Karen L. has extensive work experience in finance and accounting. Karen began their career as an auditor at Ernst & Young and a local CPA firm in 1996. From 2001 to 2009, they served as a Controller at Monogram Biosciences. Karen then joined iPierian as a Corporate Controller from 2009 to 2013 before moving to True North Therapeutics as a Sr. Director, Corporate Controller from 2013 to 2017. Karen then took on the role of VP, Finance & Corporate Controller at RAPT Therapeutics from 2017 to 2021. Karen is currently employed as the SVP, Finance & Corporate Controller at Neuron23 Inc.

Karen L. attended San Francisco State University, Lam Family College of Business, where they studied Accounting and Internal Audit. The start and end dates of their education are not specified.